1. Pink Sheet
  2. >>Legislation

Political Trials On All Sides: Lilly CEO Laments Loss Of ‘Chamber of Commerce Republicans’

 
• By Sarah Karlin-Smith

David Ricks says the challenging political environment is empowering regulators. The Lilly leader also talked Twitter and drug prices, in a STAT Summit interview.

US Chamber of Commerce
Anti-corporate sentiment on both sides of the aisle is emboldening regulators and hurting pharma, Lilly CEO says • Source: Shutterstock

A difficult political environment for corporations has resulted in non-elected regulators being granted “more latitude,” creating new challenges and unpredictability for the drug industry, Eli Lilly and Company CEO David Ricks said.

“We’re getting I think some different behavior that is hard to plan around, whether it be from the FTC or FDA or other agencies, and that’s not good for investment

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Pink Sheet

EMA Explores Using AI Language Models To Refine Oncology Guidance

 
• By Vibha Sharma

The European Medicines Agency has for the first time explicitly stated it is considering the use of large language models as a tool to improve the readability of a scientific guideline.

Industry On Making England’s HTA Innovation Lab A Success

 
• By Eliza Slawther

England’s health technology assessment institute, NICE, must ensure that there is clarity for manufacturers on how its methods and processes might change following testing in its sandbox environment, the Association of the British Pharmaceutical Industry said.

US FDA Rare Disease Case Studies Provide Development Models For Sponsors

 
• By Laura Helbling

Sanofi’s Xenpozyme and Sentynyl’s Nulibry are the first two case studies the FDA is using to continue educating rare disease sponsors on best practices.